Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
11.29
-0.35 (-3.01%)
At close: Dec 31, 2025, 4:00 PM EST
11.30
+0.01 (0.09%)
After-hours: Dec 31, 2025, 7:53 PM EST
Biohaven Employees
Biohaven had 256 employees as of December 31, 2024. The number of employees increased by 17 or 7.11% compared to the previous year.
Employees
256
Change (1Y)
17
Growth (1Y)
7.11%
Revenue / Employee
n/a
Profits / Employee
-$3,047,305
Market Cap
1.50B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BHVN News
- 6 days ago - US Stocks Mixed; Biohaven Shares Fall - Benzinga
- 6 days ago - Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise - Seeking Alpha
- 6 days ago - Biohaven Misses The Mark In Depression Trial, Stock Falls - Benzinga
- 6 days ago - Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus - Benzinga
- 8 days ago - Biohaven's depression drug fails mid-stage trial, shares fall - Reuters
- 8 days ago - Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder - PRNewsWire
- 21 days ago - Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress - PRNewsWire
- 7 weeks ago - Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M - PRNewsWire